Annual Cash & Cash Equivalents
$24.57 M
-$15.31 M-38.39%
December 1, 2024
Summary
- As of March 14, 2025, ACRS annual cash & cash equivalents is $24.57 million, with the most recent change of -$15.31 million (-38.39%) on December 1, 2024.
- During the last 3 years, ACRS annual cash & cash equivalents has fallen by -$2.78 million (-10.16%).
- ACRS annual cash & cash equivalents is now -56.91% below its all-time high of $57.02 million, reached on December 31, 2018.
Performance
ACRS Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$24.57 M
-$23.08 M-48.44%
December 1, 2024
Summary
- As of March 14, 2025, ACRS quarterly cash and cash equivalents is $24.57 million, with the most recent change of -$23.08 million (-48.44%) on December 1, 2024.
- Over the past year, ACRS quarterly cash and cash equivalents has dropped by -$15.31 million (-38.39%).
- ACRS quarterly cash and cash equivalents is now -78.34% below its all-time high of $113.45 million, reached on June 30, 2021.
Performance
ACRS Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ACRS Cash And Cash Equivalents Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -38.4% | -38.4% |
3 y3 years | -10.2% | -10.2% |
5 y5 years | -28.1% | -54.5% |
ACRS Cash And Cash Equivalents Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -45.7% | at low | -64.0% | +7.6% |
5 y | 5-year | -45.7% | +11.4% | -78.3% | +11.4% |
alltime | all time | -56.9% | +156.3% | -78.3% | +149.4% |
Aclaris Therapeutics Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Dec 2024 | $24.57 M(-38.4%) | $24.57 M(-48.4%) |
Sep 2024 | - | $47.65 M(+108.7%) |
Jun 2024 | - | $22.83 M(-36.3%) |
Mar 2024 | - | $35.84 M(-10.1%) |
Dec 2023 | $39.88 M(-11.9%) | $39.88 M(+2.1%) |
Sep 2023 | - | $39.04 M(+25.3%) |
Jun 2023 | - | $31.15 M(-30.3%) |
Mar 2023 | - | $44.72 M(-1.2%) |
Dec 2022 | $45.28 M(+65.6%) | $45.28 M(-26.6%) |
Sep 2022 | - | $61.65 M(-9.7%) |
Jun 2022 | - | $68.26 M(+87.8%) |
Mar 2022 | - | $36.34 M(+32.9%) |
Dec 2021 | $27.35 M(+24.0%) | $27.35 M(-49.0%) |
Sep 2021 | - | $53.60 M(-52.8%) |
Jun 2021 | - | $113.45 M(+221.7%) |
Mar 2021 | - | $35.27 M(+59.8%) |
Dec 2020 | $22.06 M(-35.5%) | $22.06 M(-6.7%) |
Sep 2020 | - | $23.64 M(-27.4%) |
Jun 2020 | - | $32.59 M(-39.6%) |
Mar 2020 | - | $53.99 M(+57.9%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2019 | $34.19 M(-40.0%) | $34.19 M(+14.3%) |
Sep 2019 | - | $29.90 M(-5.5%) |
Jun 2019 | - | $31.65 M(-7.4%) |
Mar 2019 | - | $34.20 M(-40.0%) |
Dec 2018 | $57.02 M(+182.2%) | $57.02 M(+114.4%) |
Sep 2018 | - | $26.59 M(-42.2%) |
Jun 2018 | - | $46.03 M(-16.1%) |
Mar 2018 | - | $54.88 M(+171.7%) |
Dec 2017 | $20.20 M(-33.0%) | $20.20 M(-66.4%) |
Sep 2017 | - | $60.05 M(+83.6%) |
Jun 2017 | - | $32.71 M(+38.1%) |
Mar 2017 | - | $23.68 M(-21.5%) |
Dec 2016 | $30.17 M(+206.3%) | $30.17 M(+69.5%) |
Sep 2016 | - | $17.80 M(-44.1%) |
Jun 2016 | - | $31.82 M(+142.3%) |
Mar 2016 | - | $13.13 M(+33.3%) |
Dec 2015 | $9.85 M(-8.4%) | $9.85 M(-61.2%) |
Sep 2015 | - | $25.42 M(+158.0%) |
Jun 2015 | - | $9.85 M(-8.4%) |
Dec 2014 | $10.76 M(+12.2%) | $10.76 M |
Dec 2013 | $9.59 M | - |
FAQ
- What is Aclaris Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Aclaris Therapeutics?
- What is Aclaris Therapeutics annual cash & cash equivalents year-on-year change?
- What is Aclaris Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Aclaris Therapeutics?
- What is Aclaris Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Aclaris Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of ACRS is $24.57 M
What is the all time high annual cash & cash equivalents for Aclaris Therapeutics?
Aclaris Therapeutics all-time high annual cash & cash equivalents is $57.02 M
What is Aclaris Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, ACRS annual cash & cash equivalents has changed by -$15.31 M (-38.39%)
What is Aclaris Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ACRS is $24.57 M
What is the all time high quarterly cash and cash equivalents for Aclaris Therapeutics?
Aclaris Therapeutics all-time high quarterly cash and cash equivalents is $113.45 M
What is Aclaris Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, ACRS quarterly cash and cash equivalents has changed by -$15.31 M (-38.39%)